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Abstract
Background: To evaluate the cost-effectiveness of trimetazidine (TMZ) as add-on therapy to standard-of-care (SoC)
compared to SoC alone in patients with chronic stable angina who did not respond adequately to first line therapy
with b-blockers, nitrates or calcium channel antagonists in Greece.
Methods: A Markov model with 3-month cycles and 1-year time horizon was developed to assess the comparators.
The analysis was conducted from a third-party payer perspective. The clinical inputs and utility values were
extracted from the published literature. Resource consumption data were obtained from local experts, using a
questionnaire developed for the purpose of the study and were combined with unit cost data (in €2016) obtained
from official sources. Cost effectiveness was assessed by calculating the incremental cost effectiveness ratio (ICER).
Probabilistic sensitivity analysis (PSA) was performed to account for uncertainty and variation in the input
parameters of the model.
Results: The analysis showed that the cost of TMZ plus SoC was €1755.57 versus €1751.76 of SoC alone. In terms of
health outcomes, TMZ plus SoC was associated with 0.6650 QALYs versus 0.6562 QALYs for SoC alone. The incremental
analysis resulted in an ICER of €430.67 per QALY gained. PSA revealed that the probability of TMZ plus SoC being
cost-effective over SoC was 89 %, at a threshold of €34,000 per QALY gained.
Conclusion: The results indicate that TMZ as add –on treatment may be a highly cost-effective option for the
symptomatic treatment of patients with chronic stable angina in Greece relative to SoC alone.
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Background
Chronic stable angina is a clinical syndrome of temporary
hypoxic ischemic status caused mainly by persistent cor-
onary stenosis induced heart load increase [1]. There is
increased body of evidence indicating that chronic stable
angina strongly affects patient’s quality of life, and patients
with chronic stable angina are more likely to have depres-
sion [2, 3] or impaired sexual functioning [4] and insom-
nia compared to the general population. Moreover, there
are indications that patients with moderate or severe
angina have more than a twofold higher mortality risk
compared to those with minimal or mild angina [5].
Apart from the humanistic burden, chronic stable
angina may incur great economic consequences for the
payers health care systems [6] and society overall, as this
condition leads to higher healthcare resource utilization,
such as medication and hospitalizations, including in
many occasions expensive vascular interventions and loss
of productive time. More specifically, hospitalizations have
been found to be the main cost driver of burden, as they
account for almost two thirds of the total chronic stable
angina-related health care expenditures, mainly due to the
expensive invasive procedures required for the manage-
ment of patients [6, 7]. Additionally, studies have shown
that chronic stable angina leads to substantial productivity
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loss [8]. In this light, studies have revealed that the total
cost (both direct and indirect) of chronic angina is 2 to 3
times higher compared to the direct chronic angina cost
alone [8].
In this context, the effective management of chronic
stable angina is paramount for clinical and economic
reasons. The aim of patient management in chronic
stable angina is to relieve symptoms, to improve quality
of life and to prevent cardiovascular events. Lifestyle
modification, pharmacological therapy and revasculari-
zation procedures represent the cornerstones in man-
agement of chronic stable angina [9–11].
The usual pharmacological therapy utilized includes
nitrates, beta-blockers, calcium channel blockers, anti-
platelets, statins, renin-angiotensin-aldosterone system
blockers etc [9–12]. Despite the aggressive use of con-
ventional antianginal therapies, many patients remain
symptomatic [13]. For this reason, new classes of treat-
ment with different mechanisms of action have been
evaluated recently for the management of chronic stable
angina [12, 14–17]. Trimetazidine (TMZ- Vastarel®) is one
such novel antianginal agent [18]. TMZ is a pure meta-
bolic agent that induces the myocardium to shift from free
fatty acids to predominantly glucose utilization in order to
increase adenosine triphosphate (ATP) generation per unit
oxygen consumption [19, 20]. In clinical studies TMZ has
reduced the frequency of angina episodes and improved
exercise performance without affecting hemodynamic
parameters [21, 22]. In 2012 the European Medicines
Agency (EMA) finished a review of benefits and risks of
TMZ and approved its use as add-on therapy for the
symptomatic treatment of adult patients with chronic
stable angina, who are inadequately controlled by or are
intolerant to first-line antianginal therapies [23].
Although it is proven that TMZ represents an effective
treatment option for the management of chronic stable
angina, it may also impose an additional tangible cost to
the health care system and payers. This raises the question
as to whether TMZ offers good “value”, in other words a
benefit which is worth the investment.
In this light, the aim of the present study was to evalu-
ate the cost-effectiveness of TMZ as add-on therapy to
standard-of-care (SoC) compared to SoC alone, in pa-
tients with chronic stable angina who did not respond
adequately to first line therapy with b-blockers, nitrates
or calcium channel antagonists, in the healthcare setting
of Greece.
Methods
A Markov model with 3-month cycles and 1-year time
horizon was developed to evaluate the cost-effectiveness
of TMZ 35 mg b.i.d as add-on therapy to SoC compared
to SoC alone in patients with chronic stable angina. The
analysis was conducted from a third-party payer (National
Sickness Fund—EOPYY) perspective. Because the time
horizon did not exceed 1 year, no discounting was neces-
sary for both cost and health outcomes. The model was
set up to calculate the incremental cost incurred and the
incremental quality adjusted life years (QALYs) gained
using TMZ as add-on treatment for the management of
stable angina patients. The cost-effectiveness of TMZ was
expressed as an incremental cost effectiveness ratio
(ICER). The model was stochastic to allow probabilistic
sensitivity analysis.
Model structure
The model consists of 5 health states, four of which re-
flect the severity of chronic stable angina (minimal, mild,
moderate, severe) and the other is the absorbing health
state of death (Fig. 1). The frequency of angina episodes
was used as the main indicator to define angina severity,
as follows: 1) minimal angina: episodes occur less than
once a week or not at all; 2) mild angina: occur weekly;
3) moderate angina: indicates having symptoms several
times per week to every day; and 4) severe angina:
reflects having angina several times per day [5, 24].
Patients enter the model in one of the three most se-
vere angina frequency health states (mild, moderate or
severe angina) and are assumed to receive TMZ plus
SoC or SoC alone. Then, on a cycle basis, patients can
transit to one of the other health states, dependent upon
specific treatment-related probabilities. For example, pa-
tients who enter the model at the mild state may remain
in the same state after a 3-month period or move into the
minimal, moderate, and severe or death states. Patients
may transit from one health state to another during the
first 3 months (i.e. 1 cycle), to be in line with the follow-
up period of the VASCO trial [25]. In absence of long-
term efficacy data for trimetazidine, from the 2nd cycle
and onwards, living patients are assumed to remain in the
same angina health state for the remainder of the model’s
time horizon, or until death.
Clinical Inputs
The clinical inputs considered in the model were: a)
transition probabilities which reflect the probability of
patients moving from one health state to another b) the
baseline distribution of patients across the health states
that reflect the angina severity, and the c) utility values
related to angina severity. For the purpose of the present
analysis these data were obtained from the VASCO [25]
clinical trial and other published studies [5, 26].
Transition Probabilities
The transition probabilities for patients treated with
TMZ 35 mg b.i.d were extracted from the corresponding
arm of VASCO trial [25] (Table 1), while the transition
Kourlaba et al. BMC Health Services Research  (2016) 16:520 Page 2 of 8
probabilities for patients receiving SoC were derived
from the comparator arm of the same trial.
Regarding transition probabilities to death, mortality
data were modelled to be conditional upon the angina
severity health state, but not treatment used, as no
mortality data specifically related to TMZ are available.
These mortality rates were derived from a prospective
cohort study of coronary artery disease patients from 6
Veterans Affairs General Internal Medicine Clinics that
reported annual mortality stratified by angina frequency
using the SAQ [5]. These data have been already used
elsewhere [24]. The annual mortality data were converted
to 3-month transition probabilities using the formula
(Table 2): Pmonthly = 1-exp(-(-ln(1-P12-month))*1/4).
Target population
The target population consisted of a hypothetical patient
cohort suitable for being treated with both alternatives.
In particular, the base case analysis was conducted for
symptomatic patients (>1 angina attacks/week). The
baseline distribution of patients across the health states
was obtained from VASCO trial (Table 2) [25].
Utility weights
QALYs were calculated by multiplying the time spent in
each health state by corresponding EuroQol-5D utility
estimates for each angina severity health state. Utility
values range from 0 to 1, where 1 represents perfect
health and 0 represents death. Utility values were obtained
from the literature (Table 2) [26] and have been used
previously in a similar study [27].
Costing Methodology
The economic evaluation was conducted from a third-
party-payer perspective and as such only health care costs
reimbursed by the payer were considered. Hence other
costs, such as those related to the central Government
budget to cover personnel salaries or patient copayments,
were not considered. The average resource consumption
for a Greek patient suffering from chronic stable angina
was obtained from two local key opinion leaders (KOLs)
Death
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Fig. 1 Graphical representation of model structure
Table 1 Clinical inputs (3-month probabilities) per therapy arm
and severity state
Angina severity state at the end of the 3-month period
Angina severity
state at baseline
Minimal Mild Moderate Severe Source
TMZ 70 mg/d + SoC
Minimal 94.66 % 4.20 % 1.15 % 0.00 %
VASCO trial
[25]
Mild 52.72 % 41.30 % 5.43 % 0.54 %
Moderate 19.42 % 61.17 % 15.53 % 3.88 %
Severe 14.29 % 18.10 % 24.76 % 42.86 %
SoC
Minimal 90.61 % 9.39 % 0.00 % 0.00 %
Mild 46.60 % 41.88 % 9.42 % 2.09 %
Moderate 25.84 % 43.82 % 23.60 % 6.74 %
Severe 11.72 % 26.56 % 15.63 % 46.09 %
TMZ Trimetazidine, SoC Standard of Care











Minimal 4.60 % 0 % 0.81
Mild 4.80 % 47 % 0.75
Moderate 8.10 % 26 % 0.60
Severe 10.90 % 27 % 0.39
aSpertus et al [5]
bVASCO trial [25]
cLongworth et al [26]
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in the field of cardiology. The questionnaire developed for
the purpose of the study is presented in Additional file 1.
Costs considered in the model include hospitalizations,
vascular interventions, outpatient management, medica-
tion use, and laboratory and diagnostic examinations. All
costs refer to the year 2016 (€).
Drug acquisition cost of anti-anginal drugs
Drug acquisition costs for TMZ and SoC were calculated
using the latest price bulletin issued by the Ministry of
Health (31.12.2015) [28] as well as the corresponding
reimbursement prices (Positive List for the reimbursement
of medicines, Ministry of Health: Official Government
Gazzete, FEK 416/19.2.2016). Reimbursement prices were
reduced by the patient relevant patient co-payment (25 %)
and relevant rebates (Official Government Gazzete, FEK
64/16.1.2014). In particular, the rebate of 9 % given by
manufacturers to get into the positive list was considered
in the analysis. For TMZ only, an additional rebate of
2 % was considered as it is alone in its cluster (Official
Government Gazzete, FEK 416/19.2.2016). It is noted
that the volume-related rebate ranging from 2 to 12 %
could have been considered in the analysis. Due to lack
of volume–related data for all drugs, it was not taken
into account in the base case analysis, but scenario ana-
lyses were explored in sensitivity analysis.
SoC drug costs have been estimated using the pro-
portion of patients using each therapeutic class, as
obtained from data provided by the local KOLs and
data extracted from the Greek population enrolled in
the CLARIFY study[29]. The mean daily drug dose
was also reported by the local KOLs and the relevant
drug acquisition costs for each category were calcu-
lated as mentioned above. Data obtained from the
CLARIFY study and local KOLs were considered more
appropriate than the VASCO trial, as they reflect more
accurately the common clinical practice in Greece and
ensure the applicability of our results to the Greek
setting.
For each therapeutic class, the active substances (INN)
considered in the analysis reflected the most commonly
prescribed in Greece, as obtained from the local KOLs
(Additional file 2). Hence, a weighted cost was calculated
for each therapeutic class based on the distribution of
patients to different active substances. Regarding the
drug acquisition cost of TMZ, a daily dose of 35 mg
b.i.d, which reflects the common clinical practice in
Greece, was considered to be aligned with the dose used
in the VASCO trial [25] from which efficacy data were
extracted. Based on this approach, the monthly weighted
cost to payer for SoC in Greece was calculated at €23.40
and the monthly cost of TMZ 70 mg/d plus SoC at
€29.18
Hospitalization costs
To estimate the total annual hospitalization cost (exclud-
ing hospitalizations related to vascular interventions) per
therapy arm, the reimbursed cost per hospitalization to
intensive care unit (ICU) and cardiac care clinic were
obtained from the Government Gazette (FEK A’3054/18-
11-2012) and the Diagnostic Related Groups (DRGs)
tariffs issued by the Greek Ministry of Health, [30] re-
spectively. These were multiplied by the proportion of
patients requiring hospitalization and the hospitalization
rate (frequency of hospitalizations) as obtained from the
local KOLs. The annual hospitalization cost was found to
range from €5 in patients experiencing minimal angina
episodes to €1429 in patients experiencing severe angina
episodes (Table 3).
Regarding the cost of vascular interventions, the pro-
portion of patients with chronic stable angina undergo-
ing revascularization, such as percutaneous coronary
intervention (PCI) or coronary artery bypass grafting
(CABG), in clinical practice in Greece, as obtained from
local KOLs, was combined with the reimbursed cost per
revascularization as obtained from the DRGs tariffs is-
sued by the Greek Ministry of Health [30]. The annual
cost of vascular interventions was found to range from
€586 in patients experiencing minimal angina episodes
to €1973 in patients experiencing severe angina episodes
(Table 3). To account for the effect of angina severity on
the cost of hospitalizations, the model allowed the pro-
portion of patients requiring hospitalization (with and
without revascularization) and the hospitalization fre-
quency to depend upon angina severity.
Routine Monitoring costs
The routine monitoring costs reflect outpatient visits, la-
boratory tests and diagnostic tests undertaken. The num-
ber of visits, laboratory tests and diagnostic tests required
as well as the proportion of patients undergoing each test
were retrieved from local KOLs. The corresponding reim-
bursed unit costs were obtained from the Government
Gazette (FEK A’262/16-12-2011) and from the official site
of EOPYY, respectively. The annual cost for outpatient
visits was found to range from €8 in patients suffering
from minimal angina to €77 in those suffering from severe
angina. With respect to laboratory and diagnostic tests, it
was found that the annual laboratory test cost varies from
€20 to €62 and the annual diagnostic tests cost from €42
to €122 (Table 3). As with the hospitalizations, the model
allowed the proportion of patients undergoing to labora-
tory and diagnostic tests as well as the number of tests
and visits to depend on angina severity.
Analyses
The aforementioned data were used to estimate mean
QALY gain and total mean direct costs attributable to
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each comparator. The cost-effectiveness of TMZ plus
SoC compared to SoC alone was evaluated by calculat-
ing the incremental cost per QALY gained (ICER). For a
treatment to be considered cost-effective a willingness-
to-pay (WTP) threshold of €34,000 per QALY was used
as a benchmark in the current analysis. This is based on
the World Health Organization (WHO) guidelines
which indicate that a treatment is highly cost-effective
when the ICER is below the annual Gross Domestic
Product (GDP) per capita and it remains cost-effective if
the ICER is between 1 and 3 times the GDP per capita
of the country for which the analysis is undertaken [31].
Due to critical financial situation of the country at
present we have set a maximum limit at 2 times the an-
nual GDP per capita, the latter estimated at about
€17,000 from the International Monetary Fund (IMF) at
current prices [32].
The majority of input data used in the current model are
subjected to uncertainty. Probabilistic sensitivity analysis
(PSA) was therefore performed using second-order Monte
Carlo simulation. In this analysis, probability distribution
was assigned around each parameter (i.e. costs—excluding
drug acquisition costs-, transition probabilities etc) and the
economic and health outcomes were generated multiple
times by drawing samples from the distributions. Distribu-
tions were selected according to the nature of the variables
utilized [33]. In particular, a gamma distribution was used
to represent the uncertainty in costs, because costs are
constrained on the interval zero to positive infinity and are
often highly positively skewed. Resource use data follow
discrete Poisson-distributions, whose conjugate distribu-
tion to describe the mean are the gamma distribution.
Binomial parameters and utility values are constricted on
the interval zero to one and hence they were varied
according to a beta distribution. For multinomial data such
as transition probabilities, a Dirichlet distribution was used.
In total, 5000 estimates of costs, QALYs, and ICERs. A
cost-effectiveness acceptability curve (CEAC) was plotted,
showing the proportion of simulations that are considered
cost-effective at different levels of WTP for a QALY.
Finally, to assess the impact of the assumptions con-
sidered in the base case analysis, one-way sensitivity
analyses (OWSA) was undertaken to test the robustness
of the results, by varying individual parameters between
low and high values, in order to ascertain the key
drivers of cost-effectiveness. The upper and lower
bounds of all parameters were set at ±20 and ±10 % for
cost and clinical inputs respectively (assumption) of the
base case values.




The analysis showed that TMZ plus SoC was marginally
more costly than Soc alone (€1755.57 versus €1751.76).
Among the cost categories considered, vascular inter-
ventions accounted for 56 % and 58 % of total costs in
TMZ plus SoC and SoC alone, respectively. Following
vascular interventions, hospitalization cost (without
vascular intervention) made up 17 % and 18 % of the
total annual cost related to TMZ plus SoC and SoC
alone, respectively, and drug acquisition cost accounted
for 19 % and 16 % of the total costs, respectively. The
remaining medical costs (i.e. laboratory tests, diagnostic
tests and physician visits) represented only a small pro-
portion of overall costs.
In terms of health outcomes, the analysis revealed that
TMZ plus SoC was marginally more effective compared
to SoC alone. Patients who received TMZ plus SoC
gained 0.6650 QALYs while patients who received SoC
alone gained 0.6562 QALYs. Under the base case as-
sumptions, incremental analysis showed that TMZ plus
SoC was more effective and more costly than SoC result-
ing in an ICER of €430.67 per QALY gained well below
the predetermined WTP threshold (Table 4).
One-way sensitivity analysis
The OWSA revealed that the results of the model were
more sensitive to the transition probability of moderate
to mild angina of patients treated with TMZ plus SoC as
this parameter was found to have the greatest effect on
ICER, followed by the transition probabilities of severe
to mild angina and moderate to mild of patients treated
with SoC (Fig. 2). It is worth noting that in all parame-
ters considered in the sensitivity analysis the TMZ plus
SoC remains a cost—effective treatment, since the ICER
per QALY gained remains well below of the threshold of
Table 3 Medical costs per category and severity stage
Total annual cost per angina
severity
Minimal Mild Moderate Severe
Outpatient visits a(in €) 8.00 15.75 39.88 76.50
Diagnostic tests b(in €) 41.62 62.05 101.00 122.37
Laboratory tests b(in €) 20.41 25.63 45.31 61.24
Hospitalization without
revascularization c(in €)
4.67 35.03 331.06 1428.63
Hospitalization with
revascularization c(in €)
586.24 683.62 1583.23 1972.77
Official Source
aThe cost of physician visit was obtained from government gazette
(FEK A’262/16-12-2011)
bThe cost of diagnostic & laboratory tests was obtained from official site
of EOPYY
cThe cost of hospitalization without revascularization such as intensive care
unit & cardiac clinic were obtained from government gazette (FEK A’3054/18-
11-2012) and Diagnostic Related Groups (DRG) (average cost of DRG code:
K32A, K32M, K47M, K47X)
dThe cost of hospitalization with revascularization such as PCI&CABG were
obtained from DRG (average cost of DRG code: K15X, K10M, K15M for PCI and
average cost of DRG code: K05M, KO5X for CABG)
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€34,000 per QALY gained. Moreover, when a volume
rebate of 2 and 12 % on reimbursed drug prices of TMZ
and SoC was considered in analysis, the TMZ plus SoC
was a cost-effective (ICER: €273 per QALY gained) and
dominant (less costly, more effective) alternative over
SoC respectively.
Probabilistic sensitivity analysis
The PSA confirms the deterministic results. In particular,
the analysis showed that TMZ plus SoC is more cost-
effective than SoC for the majority of iterations. The
CEAC showed that the likelihood of TMZ plus SoC being
cost-effective at a WTP of €34,000/QALY was found to be
89 % compared to SoC alone [Fig. 3].
Discussion
In the present study, a Markov model was developed to
evaluate the cost effectiveness of TMZ as add-on ther-
apy to SoC compared to SoC alone during a 1-year time
horizon in patients with chronic stable angina in
Greece. The analysis was conducted from a third-party
payer perspective such as only direct medical costs
were considered in the analysis. To the best of our
knowledge, this is the first study aiming to evaluate the
cost effectiveness of TMZ as add-on therapy to SoC
compared to SoC.
The current analysis showed that TMZ as add-on
therapy to SoC was slightly more costly treatment as it
was found that the total treatment cost was higher by
€3.81 compared to SoC alone over a 1-year time hori-
zon. In terms of health outcomes, TMZ was more effect-
ive resulting in an ICER equal to €430.67 per QALY
gained, well below the predetermined WTP threshold of
€34,000 per QALY gained. This finding seems to be rea-
sonable as the modest increased cost of medicines in
TMZ plus SoC arm, was partially offset by expected re-
ductions in hospitalization and vascular interventions
costs compared to SoC alone. To examine the robust-
ness of this finding, an OWSA was conducted. TMZ
plus SoC remained a cost-effective alternative even when
a 20 % increase at the acquisition cost of TMZ was con-
sidered in the analysis.
Our findings in combination with the clinical benefits
provided by TMZ such as the statistically significantly
greater improvement of total exercise duration and time
to 1-mm ST segment depression compared to placebo
indicates that TMZ is a favorable choice for the manage-
ment of chronic stable angina compared to placebo.
Moreover, it should be noticed that no difference has
been identified in serious adverse events between TMZ
and placebo indicating that TMZ is well-tolerated [34].





Total cost (€) 1755.57 1751.76 3.82
Drug acquisition cost (€) 341.36 273.61 67.75
Hospitalization cost (€) 293.63 320.72 −27.09
Outpatient visits cost (€) 26.89 28.28 −1.39
Vascular interventions cost (€) 990.01 1022.87 −32.87
Diagnostic tests cost (€) 71.22 72.93 −1.71
Laboratory tests cost (€) 32.47 33.35 −0.88
Health Outcomes
QALYs 0.6650 0.6562 0.0088
LYs 0.9747 0.9743 0.0004
Incremental analysis
ICER per QALY (€) 430.67
ICER Incremental cost effectiveness ratio, QALYs Quality-adjusted life years, LYs
Life years, TMZ Trimetazidine, SoC Standard of Care
Fig. 2 Tornado diagram of one-way sensitivity analysis
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Although the methodology adopted followed standard
conventions and various sensitivity analyses were con-
ducted to fully explore uncertainty, several potential lim-
itations to this study should be considered. First of all, in
the present analysis it was assumed that the clinical and
utility data obtained from the published studies [5, 25,
26] were applicable to the Greek health care setting. The
use of this data may be challenged; however, given the
absence of local data this choice was unavoidable. One
may argue that pivotal trials such as VASCO are almost
universally used to build models for pricing and reim-
bursement decisions. Moreover, it is worth noting that
the profile of Greek patients, including smoking habits,
co-morbidities, medical history, age and body mass
index, as described in the CLARIFY study [29], is com-
parable with that of participants in VASCO. This finding
enhances the application of VASCO results to the Greek
population. However, the mean age of Greek patients
seems to be lower than that of the cohort of patients
from Veterans Affairs General Internal Medicine Clinics
from which mortality data was extracted; something that
may introduce a bias in our estimations. Nevertheless, in
absence of more relevant data, the use this mortality
data was unavoidable.
Secondly, in the absence of local data, resource utilization
was estimated by local experts. This may raise concerns
about the subjectivity of model inputs and leave space for
challenging the study results. Nonetheless, the experts par-
ticipating in the study are well-known cardiologists with ex-
tensive clinical experience on the management of chronic
stable angina, and were consistent in their views.
Thirdly, the 1-year time horizon sounds very short to
assess the cost-effectiveness of a treatment for a chronic
condition. However, long-term TMZ efficacy data as well
as mortality data are completely lacking from the litera-
ture. This is the reason that in the vast majority of stud-
ies aiming to evaluate the cost effectiveness of the
management of chronic stable angina such a short time
horizon is considered. Fourthly, the efficacy of TMZ was
applied only in the first 3 months of our analysis assum-
ing that the effect achieved at the end of the 3rd month
remains till death or the end of analysis. This assump-
tion may overestimate of underestimate the health bene-
fit related to TMZ used. However, there are no long-
term efficacy data for TMZ available, and any extrapola-
tion was not feasible as we did not have any access to
the raw data of VASCO trial. At this point, it should be
noted that.
Conclusion
In conclusion, the ICERs obtained in different scenarios
of the present study are very much below established
benchmarks, and hence the present results indicate that
TMZ as add–on treatment is a highly cost-effective al-
ternative for the symptomatic treatment of patients with
chronic stable angina in Greece.
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